Neostem (NBS) 2.25 $NBS
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 4.12 (-0.20), NBS: 2.25 (-0.09), CLSN: 1.40 (-0.02), JNJ: 117.01 (+0.01), ABBV: 61.00 (+0.25), EXEL: 7.38 (+0.01), ONCY: 0.33 (-0.02), CERU: 2.32 (+0.02), PFE: 35.29 (-0.02), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), CLVS: 14.11 (-1.12), AZN: 27.97 (-0.99), MRK: 56.81 (-0.37), NVS: 78.94 (-1.57)
Critical Limb Ischemia Therapeutics Pipeline Review, H1 2015 - 18 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc45jz/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bioheart, Inc. - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Multi Gene Vascular Systems Ltd - NeoStem, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group plc - Stempeutics Research Private Limited - TikoMed AB - Vericel Corporation - ViroMed Co., Ltd. Drug Profiles - ACP-01 - AdipoCell - Alecmestencel-T - AMR-001 - ASCT-01 - Autologous Vascular Cells Therapy - beperminogene perplasmid - Cell Therapy for Critical Limb Ischemia - Cellgram for Severe Lower Limb Ischemia - DVC1-0101 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - ixmyelocel-T - JVS-100 - MultiGeneAngio - MultiStem - PLX-PAD - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Protein for Critical Limb Ischemia - Refacell-CLI - ReN-009 - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Stempeucel - Stromal Cell Therapy for Critical Limb Ischemia - TM-700 - VM-202 For more information visit http://www.researchandmarkets.com/research/sc...tical_limb
VCEL: 2.43 (-0.07), PSTI: 1.48 (-0.04), NBS: 2.25 (-0.09), ATHX: 2.38 (+0.03)
Global Market Study on UCB Banking 2015: Asia-Pacific to Witness Highest Growth by 2020
M2 - Wed Jul 08, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7m2q2/global_market) has announced the addition of the "Global Market Study on UCB Banking: Asia-Pacific to Witness Highest Growth by 2020" report to their offering. The global UCB banking market was valued at 10,900 million in 2010 and it expanded to USD 12,774.8 million in 2013. North America has the largest market share, followed by Europe and Asia-Pacific, in the global UCB banking market. Globally, increasing prevalence of chronic diseases coupled with the emerging field of regenerative medicines is driving the UCB banking market. In addition, various government associations and initiatives are also supporting in the growth of the UCB banking market. North America has the largest market for UCB banking. The U.S., followed by Canada, is the largest market for UCB banking in the region. Increasing prevalence of chronic diseases is the key driver of the UCB banking market. In addition, initiatives by various government associations have also led to the increase in awareness about the importance of cord blood donation in the region. In Europe, the UCB banking market is growing due to increased awareness about potential applications of cord blood in the treatment of life-threatening diseases. In addition, increasing number of live births is also playing a vital role in the growth of UCB banking market in Europe. For instance, according to Eurostat, in 2010, 807,271 live births registered in 2010 and the number reached to 812,970 by 2013 in the U.K.. Due to increased awareness about potential of cord blood, newborns family donates and preserves cord blood either in private or public banks in Europe. However, Asia-Pacific is the fastest growing region in the UCB banking market. This is due to increasing prevalence of chronic diseases in the region. In addition, raising awareness about potential applications of cord blood and increasing number of live births are also contributing in the growth of UCB banking market in the region. China has the highest number of live births, followed by India around the world. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Therapeutic Application of UCB Chapter 7 Market Size and Forecast by Storage Option Chapter 8 Market Size and Forecast by Geography Chapter 9 Competitive Scenario Chapter 10 Company Profiles - China Cord Blood Corporation - Cord Blood America, Inc. - Cord Blood Registry Systems, Inc. - Cordlife Group Limited - Cryo-Cell International, Inc. - Esperite N.V. - NeoStem, Inc. - Smart Cells International, Ltd. - StemCyte - ViaCord For more information visit http://www.researchandmarkets.com/research/c7...bal_market
NBS: 2.25 (-0.09), CO: 5.92 (-0.06)
Caladrius Announces Research Collaboration With the University of Southern California and California Institute of Technology
GlobeNewswire - Thu Jun 18, 6:30AM CDT
Caladrius Biosciences, Inc. (Nasdaq:CLBS), ("Caladrius" or the "Company", formerly NeoStem, Inc.), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today that it has entered into a material transfer agreement with the University of Southern California and the California Institute of Technology, concerning next-generation strategies for its core cancer technology.
NBS: 2.25 (-0.09), CLBS: 0.53 (unch)
Periodontitis Pipeline Review, H1 2015 - 5 Companies & 10 Drug Profiles
M2 - Thu Jun 11, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v4np93/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Periodontitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Periodontitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - CSL Limited - Ensoltek Co., Ltd. - Geistlich Pharma AG - Kaken Pharmaceutical Co., Ltd. - NeoStem, Inc. Drug Profiles - AMY-101 - Drug to Antagonize C5aR for Periodontitis - Drugs for Periodontitis - GM-0111 - Hesed-3000 - POD CRC-OHS - Small Molecules to Inhibit Lysine Decarboxylase for Periodontal Disease - Stem Cell Therapy for Osteoporosis and Periodontitis - taurolidine - trafermin For more information visit http://www.researchandmarkets.com/research/v4...iodontitis
NBS: 2.25 (-0.09)
Caladrius Biosciences, Inc. Finalizes Corporate Name Change From NeoStem, Inc.
GlobeNewswire - Mon Jun 08, 5:00AM CDT
Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius" or the "Company"
, a cell therapy leader with a late-stage clinical program for immuno-oncology, today announced the finalization of its corporate name change from NeoStem, Inc. to Caladrius.
NBS: 2.25 (-0.09), CLBS: 0.53 (unch)
NeoStem Announces Closing of $28,750,000 Public Offering of Common Stock
GlobeNewswire - Tue Jun 02, 3:01PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company", to be renamed Caladrius Biosciences, Inc. as of June 8, 2015), announced today the closing of a previously announced underwritten public offering of 12,500,000 shares of common stock at a public offering price of $2.00 per share. In addition, the underwriter exercised the over-allotment option to purchase an additional 1,875,000 additional shares of its common stock bringing the gross proceeds to NeoStem from this offering to $28,750,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes.
NBS: 2.25 (-0.09)
NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company
GlobeNewswire - Fri May 29, 7:26AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a biopharmaceutical company developing novel cell-based individualized medicine therapies, today announced plans to change its corporate name to Caladrius Biosciences, Inc. ("Caladrius" , effective June 8, 2015.
NBS: 2.25 (-0.09)
Stock to Watch: Neostem Down 21.3% (NBS)
Comtex SmarTrend(R) - Thu May 28, 10:18AM CDT
Neostem (AMEX:NBS) is one of today's worst performing low-priced stocks, down 21.3% to $2.07 on 7.7x average daily volume. Thus far today, Neostem has traded 4.1 million shares, vs. average volume of 533,000 shares per day. The stock has underperformed the Dow (-21.3% to the Dow's -0.4%) and underperformed the S&P 500 (-21.3% to the S&P's -0.4%) during today's trading.
NBS: 2.25 (-0.09)
NeoStem Prices $25,000,000 Public Offering of Common Stock
GlobeNewswire - Wed May 27, 5:53PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , announced today the pricing of an underwritten public offering of 12,500,000 shares of common stock at a public offering price of $2.00 per share. The gross proceeds to NeoStem from this offering are expected to be $25,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company has granted the underwriter a 45-day option to purchase up to an aggregate of 1,875,000 additional shares of its common stock to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is expected to close on or about June 2, 2015, subject to the satisfaction of customary closing conditions.
NBS: 2.25 (-0.09)
NeoStem Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed May 27, 3:01PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , announced today that it is commencing an underwritten public offering of its common stock. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
NBS: 2.25 (-0.09)
Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Review 2015
M2 - Wed May 27, 11:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rz8t2h/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeolus Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Cantex Pharmaceuticals, Inc. - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Gamida Cell Ltd. - Humanetics Corporation - Meabco A/S - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Piramal Enterprises Limited - Pluristem Therapeutics Inc. - Priaxon AG - ProCertus BioPharm Inc. - RDD Pharma Ltd. - RxBio, Inc. - Soligenix, Inc. - Terapio Corporation - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/rz8t2h/radiation
TNXP: 2.40 (-0.16), PSTI: 1.48 (-0.04), NBS: 2.25 (-0.09), ONTX: 6.28 (-0.59), CBLI: 2.61 (+0.01)
NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for Metastatic Melanoma
GlobeNewswire - Tue May 26, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a biopharmaceutical company developing novel, cell-based individualized medicine therapies, today announced the appointment of Dr. Merrick Ross, Professor of Surgery and Chief of the Melanoma Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center (MD Anderson), as the lead principal investigator for NeoStem's Intus study. The Intus study is a Phase 3 clinical trial investigating the efficacy of the Company's patient-specific targeted cancer immunotherapy candidate NBS20 (USAN = eltrapuldencel-T) in patients with stage III recurrent or stage IV metastatic melanoma.
NBS: 2.25 (-0.09)
Neostem Down 5.8%, Shares Slide into the Red (NBS)
Comtex SmarTrend(R) - Fri May 22, 10:44AM CDT
Neostem (AMEX:NBS) is one of today's worst performing low-priced stocks, down 5.8% to $2.78 on 5.1x average daily volume. Neostem has traded 1.8 million shares thus far today, vs. average volume of 350,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's -0.3%) and underperformed the S&P 500 (-5.8% to the S&P's -0.2%) during today's trading.
NBS: 2.25 (-0.09)
Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem
GlobeNewswire - Thu May 21, 2:03PM CDT
NeoStem, Inc. (Nasdaq:NBS) announced Thursday that it will receive one of the largest research grants of its kind to support its pioneering treatment for patients with stage III recurrent or stage IV metastatic melanoma, a potentially breakthrough approach that teaches the immune system which cells to attack and kill.
NBS: 2.25 (-0.09)
Tyme, Inc. Appoints Industry Veteran Robert Dickey IV as Chief Financial Officer
BusinessWire - Wed May 20, 7:30AM CDT
Tyme, Inc. (OTC QB:TYMI), a research and development company focused on developing drug candidates for the treatment of cancer, has appointed Robert Dickey IV to serve as its Chief Financial Officer (CFO). Most recently CFO of NeoStem, Inc. Mr. Dickey is a life sciences industry veteran and former investment banker with C-level and senior leadership experience in public, private, revenue stage, development stage and start-up companies. Mr. Dickey will report to Steve Hoffman, Chief Executive Officer of Tyme, Inc.
NBS: 2.25 (-0.09)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 4.12 (-0.20), NBS: 2.25 (-0.09), CLSN: 1.40 (-0.02), JNJ: 117.01 (+0.01), ABBV: 61.00 (+0.25), EXEL: 7.38 (+0.01), ONCY: 0.33 (-0.02), CERU: 2.32 (+0.02), PFE: 35.29 (-0.02), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), CLVS: 14.11 (-1.12), AZN: 27.97 (-0.99), MRK: 56.81 (-0.37), NVS: 78.94 (-1.57)
Critical Limb Ischemia Therapeutics Pipeline Review, H1 2015 - 18 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc45jz/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bioheart, Inc. - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Multi Gene Vascular Systems Ltd - NeoStem, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group plc - Stempeutics Research Private Limited - TikoMed AB - Vericel Corporation - ViroMed Co., Ltd. Drug Profiles - ACP-01 - AdipoCell - Alecmestencel-T - AMR-001 - ASCT-01 - Autologous Vascular Cells Therapy - beperminogene perplasmid - Cell Therapy for Critical Limb Ischemia - Cellgram for Severe Lower Limb Ischemia - DVC1-0101 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - ixmyelocel-T - JVS-100 - MultiGeneAngio - MultiStem - PLX-PAD - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Protein for Critical Limb Ischemia - Refacell-CLI - ReN-009 - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Stempeucel - Stromal Cell Therapy for Critical Limb Ischemia - TM-700 - VM-202 For more information visit http://www.researchandmarkets.com/research/sc...tical_limb
VCEL: 2.43 (-0.07), PSTI: 1.48 (-0.04), NBS: 2.25 (-0.09), ATHX: 2.38 (+0.03)
Global Market Study on UCB Banking 2015: Asia-Pacific to Witness Highest Growth by 2020
M2 - Wed Jul 08, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7m2q2/global_market) has announced the addition of the "Global Market Study on UCB Banking: Asia-Pacific to Witness Highest Growth by 2020" report to their offering. The global UCB banking market was valued at 10,900 million in 2010 and it expanded to USD 12,774.8 million in 2013. North America has the largest market share, followed by Europe and Asia-Pacific, in the global UCB banking market. Globally, increasing prevalence of chronic diseases coupled with the emerging field of regenerative medicines is driving the UCB banking market. In addition, various government associations and initiatives are also supporting in the growth of the UCB banking market. North America has the largest market for UCB banking. The U.S., followed by Canada, is the largest market for UCB banking in the region. Increasing prevalence of chronic diseases is the key driver of the UCB banking market. In addition, initiatives by various government associations have also led to the increase in awareness about the importance of cord blood donation in the region. In Europe, the UCB banking market is growing due to increased awareness about potential applications of cord blood in the treatment of life-threatening diseases. In addition, increasing number of live births is also playing a vital role in the growth of UCB banking market in Europe. For instance, according to Eurostat, in 2010, 807,271 live births registered in 2010 and the number reached to 812,970 by 2013 in the U.K.. Due to increased awareness about potential of cord blood, newborns family donates and preserves cord blood either in private or public banks in Europe. However, Asia-Pacific is the fastest growing region in the UCB banking market. This is due to increasing prevalence of chronic diseases in the region. In addition, raising awareness about potential applications of cord blood and increasing number of live births are also contributing in the growth of UCB banking market in the region. China has the highest number of live births, followed by India around the world. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Therapeutic Application of UCB Chapter 7 Market Size and Forecast by Storage Option Chapter 8 Market Size and Forecast by Geography Chapter 9 Competitive Scenario Chapter 10 Company Profiles - China Cord Blood Corporation - Cord Blood America, Inc. - Cord Blood Registry Systems, Inc. - Cordlife Group Limited - Cryo-Cell International, Inc. - Esperite N.V. - NeoStem, Inc. - Smart Cells International, Ltd. - StemCyte - ViaCord For more information visit http://www.researchandmarkets.com/research/c7...bal_market
NBS: 2.25 (-0.09), CO: 5.92 (-0.06)
Caladrius Announces Research Collaboration With the University of Southern California and California Institute of Technology
GlobeNewswire - Thu Jun 18, 6:30AM CDT
Caladrius Biosciences, Inc. (Nasdaq:CLBS), ("Caladrius" or the "Company", formerly NeoStem, Inc.), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today that it has entered into a material transfer agreement with the University of Southern California and the California Institute of Technology, concerning next-generation strategies for its core cancer technology.
NBS: 2.25 (-0.09), CLBS: 0.53 (unch)
Periodontitis Pipeline Review, H1 2015 - 5 Companies & 10 Drug Profiles
M2 - Thu Jun 11, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v4np93/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Periodontitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Periodontitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - CSL Limited - Ensoltek Co., Ltd. - Geistlich Pharma AG - Kaken Pharmaceutical Co., Ltd. - NeoStem, Inc. Drug Profiles - AMY-101 - Drug to Antagonize C5aR for Periodontitis - Drugs for Periodontitis - GM-0111 - Hesed-3000 - POD CRC-OHS - Small Molecules to Inhibit Lysine Decarboxylase for Periodontal Disease - Stem Cell Therapy for Osteoporosis and Periodontitis - taurolidine - trafermin For more information visit http://www.researchandmarkets.com/research/v4...iodontitis
NBS: 2.25 (-0.09)
Caladrius Biosciences, Inc. Finalizes Corporate Name Change From NeoStem, Inc.
GlobeNewswire - Mon Jun 08, 5:00AM CDT
Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius" or the "Company"
, a cell therapy leader with a late-stage clinical program for immuno-oncology, today announced the finalization of its corporate name change from NeoStem, Inc. to Caladrius. NBS: 2.25 (-0.09), CLBS: 0.53 (unch)
NeoStem Announces Closing of $28,750,000 Public Offering of Common Stock
GlobeNewswire - Tue Jun 02, 3:01PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company", to be renamed Caladrius Biosciences, Inc. as of June 8, 2015), announced today the closing of a previously announced underwritten public offering of 12,500,000 shares of common stock at a public offering price of $2.00 per share. In addition, the underwriter exercised the over-allotment option to purchase an additional 1,875,000 additional shares of its common stock bringing the gross proceeds to NeoStem from this offering to $28,750,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes.
NBS: 2.25 (-0.09)
NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company
GlobeNewswire - Fri May 29, 7:26AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a biopharmaceutical company developing novel cell-based individualized medicine therapies, today announced plans to change its corporate name to Caladrius Biosciences, Inc. ("Caladrius" , effective June 8, 2015. NBS: 2.25 (-0.09)
Stock to Watch: Neostem Down 21.3% (NBS)
Comtex SmarTrend(R) - Thu May 28, 10:18AM CDT
Neostem (AMEX:NBS) is one of today's worst performing low-priced stocks, down 21.3% to $2.07 on 7.7x average daily volume. Thus far today, Neostem has traded 4.1 million shares, vs. average volume of 533,000 shares per day. The stock has underperformed the Dow (-21.3% to the Dow's -0.4%) and underperformed the S&P 500 (-21.3% to the S&P's -0.4%) during today's trading.
NBS: 2.25 (-0.09)
NeoStem Prices $25,000,000 Public Offering of Common Stock
GlobeNewswire - Wed May 27, 5:53PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, announced today the pricing of an underwritten public offering of 12,500,000 shares of common stock at a public offering price of $2.00 per share. The gross proceeds to NeoStem from this offering are expected to be $25,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company has granted the underwriter a 45-day option to purchase up to an aggregate of 1,875,000 additional shares of its common stock to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is expected to close on or about June 2, 2015, subject to the satisfaction of customary closing conditions. NBS: 2.25 (-0.09)
NeoStem Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed May 27, 3:01PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, announced today that it is commencing an underwritten public offering of its common stock. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. NBS: 2.25 (-0.09)
Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Review 2015
M2 - Wed May 27, 11:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rz8t2h/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeolus Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Cantex Pharmaceuticals, Inc. - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Gamida Cell Ltd. - Humanetics Corporation - Meabco A/S - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Piramal Enterprises Limited - Pluristem Therapeutics Inc. - Priaxon AG - ProCertus BioPharm Inc. - RDD Pharma Ltd. - RxBio, Inc. - Soligenix, Inc. - Terapio Corporation - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/rz8t2h/radiation
TNXP: 2.40 (-0.16), PSTI: 1.48 (-0.04), NBS: 2.25 (-0.09), ONTX: 6.28 (-0.59), CBLI: 2.61 (+0.01)
NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for Metastatic Melanoma
GlobeNewswire - Tue May 26, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a biopharmaceutical company developing novel, cell-based individualized medicine therapies, today announced the appointment of Dr. Merrick Ross, Professor of Surgery and Chief of the Melanoma Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center (MD Anderson), as the lead principal investigator for NeoStem's Intus study. The Intus study is a Phase 3 clinical trial investigating the efficacy of the Company's patient-specific targeted cancer immunotherapy candidate NBS20 (USAN = eltrapuldencel-T) in patients with stage III recurrent or stage IV metastatic melanoma. NBS: 2.25 (-0.09)
Neostem Down 5.8%, Shares Slide into the Red (NBS)
Comtex SmarTrend(R) - Fri May 22, 10:44AM CDT
Neostem (AMEX:NBS) is one of today's worst performing low-priced stocks, down 5.8% to $2.78 on 5.1x average daily volume. Neostem has traded 1.8 million shares thus far today, vs. average volume of 350,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's -0.3%) and underperformed the S&P 500 (-5.8% to the S&P's -0.2%) during today's trading.
NBS: 2.25 (-0.09)
Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem
GlobeNewswire - Thu May 21, 2:03PM CDT
NeoStem, Inc. (Nasdaq:NBS) announced Thursday that it will receive one of the largest research grants of its kind to support its pioneering treatment for patients with stage III recurrent or stage IV metastatic melanoma, a potentially breakthrough approach that teaches the immune system which cells to attack and kill.
NBS: 2.25 (-0.09)
Tyme, Inc. Appoints Industry Veteran Robert Dickey IV as Chief Financial Officer
BusinessWire - Wed May 20, 7:30AM CDT
Tyme, Inc. (OTC QB:TYMI), a research and development company focused on developing drug candidates for the treatment of cancer, has appointed Robert Dickey IV to serve as its Chief Financial Officer (CFO). Most recently CFO of NeoStem, Inc. Mr. Dickey is a life sciences industry veteran and former investment banker with C-level and senior leadership experience in public, private, revenue stage, development stage and start-up companies. Mr. Dickey will report to Steve Hoffman, Chief Executive Officer of Tyme, Inc.
NBS: 2.25 (-0.09)
